France· FR:63966283
LUMYKRAS 120 mg, comprimé pelliculé
A sotorasib product containing sotorasib, registered in France by AMGEN EUROPE. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Sotorasib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX73 (sotorasib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Sotorasib · ATC L01XX73
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- SOTORASIB
- Manufacturer
- AMGEN EUROPE
- Country
- France (FR)
- ATC code
- L01XX73
- ATC class
- Sotorasib
- Defined daily dose
- 0.96 g, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093024193630 plaquettes thermoformées PVC polyéthylène PVDC aluminium de 8 comprimés
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sotorasib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLUMYKRASAmgen Europe B.V., Breda
- FinlandLUMYKRASOrifarm Oy
- IrelandLUMYKRAS 120 mg film-coated tabletsAmgen Europe B.V.,
- IcelandLumykrasAmgen Europe B.V.*
- NetherlandsLumykras 120 mg, filmomhulde tabletAmgen Europe B.V.
- NorwayLumykrasAmgen Europe B.V. (2)
- PolandLumykrasAmgen Europe B.V.
- BelgiumLumykras 120 mgAmgen Europe
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Lumykras
- Norway · Lumykras
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15814d4a-60e7-4bfe-8925-a7e61a3615d6 GET /v1/drugs/15814d4a-60e7-4bfe-8925-a7e61a3615d6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63966283",
"date_amm": "2022-01-06",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1603",
"substance": "SOTORASIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Oui"
}See everything about sotorasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.